Program Wieloletni Pn. Narodowa Strategia Onkologiczna Na Lata 2020-2030

Objectives

Poland’s National Oncology Strategy is a 2020–2030 national framework, established under the Act of 26 April 2019, to improve cancer outcomes through a patient-centred, coordinated and comprehensive oncology system.[1]Its overarching aim is to increase five-year survival after cancer treatment, improve early detection and reduce cancer mortality, while reversing adverse epidemiological trends and reducing indirect costs associated with cancer.[2]The Strategy responds to high cancer burden, late-stage diagnosis, substantial regional inequalities in mortality and survival, fragmented care and gaps in quality oversight.[3][4][5][6]

• Reduce cancer incidence through health education, healthier lifestyles, primary prevention and reduced exposure to modifiable risk factors, particularly tobacco, unhealthy diet, excess weight, alcohol and ultraviolet radiation.[7][8][9]
• Improve secondary prevention and early detection through higher-quality breast, cervical, colorectal, lung and prostate screening, including greater participation and stronger quality assurance.[10][11][12]
• Strengthen the oncology workforce, medical education and specialist training to address shortages in oncology and haematology and prepare staff for demographic and epidemiological change.[13][14][15]
• Advance research, clinical trials, biobanking, registry analysis and innovation so that patients can access effective diagnostics, therapies and personalised treatment.[10][16][17]
• Establish equal access to high-quality, coordinated care across regions, including diagnostic and therapeutic standards, rehabilitation, psychological support, palliative care, hospice care and services that support quality of life during and after treatment.[7][10][18]

The Strategy is structured around five areas of action: workforce investment; education and primary prevention; patient investment and secondary prevention; science and innovation; and the oncology care system.[1]It includes 23 proposed actions and continues relevant directions and contracts from the earlier National Programme for Combating Cancer Diseases.[2]

Time-bound outcomes include reducing mortality from selected colorectal, breast, cervical, melanoma and lung cancers by 2025; increasing participation in oncology clinical trials to at least 6% by 2024 and 8% by 2029; ensuring coordinated oncology care for all patients by the end of 2024; and providing psycho-oncology care to every oncology patient by the end of 2029.[19][17][20]

Implementation

The Strategy combines legislative reform, annual implementation schedules, service reorganisation, workforce development, prevention, research support, quality assurance, infrastructure investment and public financing.[13][21][22]Its central delivery model is the National Oncology Network, designed to reduce dispersed and fragmented provision by organising care around patients, standardising pathways and linking providers through graded levels of specialisation.[23][24][25]

• Implement the National Oncology Network and regional coordinating centres, with regional centres coordinating care within each voivodeship and working with lower-reference providers.[25]
• Establish cancer-specific competence centres and Cancer Units, including units for lung, colorectal, gynaecological, urological, childhood and rare adult cancers.[10][25]
• Introduce uniform diagnostic, therapeutic and organisational standards, alongside mandatory accreditation for publicly funded pathology and genetic diagnostic facilities.[24][26]
• Expand prevention delivery through schools, primary healthcare, occupational medicine, public campaigns, screening invitations, vaccination, smoking-support clinics and Public Health Centres.[27][28][29]
• Strengthen specialist capacity through priority training places, higher remuneration, residency funding, revised curricula, medical-skills certification and postgraduate programmes for psycho-oncology, care coordination, medical physics and electroradiology.[30][31][32]
• Develop research infrastructure through the Medical Research Agency, clinical-trial support centres, a central clinical-trial repository, biobanks, competitive grants and expanded access to innovative therapies.[16][33][34][35]
• Modernise healthcare infrastructure and replace worn equipment supporting cancer diagnosis, treatment, pathology, genetic diagnostics, interventional radiology, clinical research and screening quality.[21][36]

The Minister of Health leads implementation, coordinates the Strategy, monitors progress and prepares an annual report for submission to the Sejm by 31 May for the preceding calendar year.[36]Subordinate or supervised units and collaborating entities must report on assigned tasks by 31 March of the following year, and the Strategy is to be updated at least every five years.[36]Annual schedules set implementation methods, activities and funding allocations after adoption of the annual Budget Act.[13][37]

Key implementing and collaborating bodies include the Ministry of Health, Ministry of Science and Higher Education, National Health Fund, Medical Research Agency, National Institute of Oncology Maria Skłodowska-Curie, State Research Institute, Medical Examinations Centre in Łódź, Centre for Postgraduate Medical Education, healthcare providers, local authorities, professional bodies, patient organisations and oncology or academic centres.[38][39][31][40][41]

Monitoring draws on the National Cancer Registry, organ-specific and screening registries, provider data, patient-needs and satisfaction surveys, quality inspections, certification and care-process monitoring.[19][26][42]The Strategy specifies annual reporting and several outcome, coverage and implementation targets, but does not provide a complete consolidated indicator framework, detailed evaluation methodology or sanctions for non-performance.[17][36]

Financing is primarily public, supplemented where specified by non-public sources, state-budget resources, European Union funds and Community programmes.[22]Planned state-budget expenditure is capped at 250 million Polish zloty in 2020, 450 million Polish zloty annually from 2021 to 2023, and 500 million Polish zloty annually from 2024 to 2030.[41]

Monitoring & Evaluation

The National Oncology Strategy combines outcome targets, service-quality monitoring, registry development and annual implementation reporting. The Minister of Health coordinates implementation, prepares an annual report, and submits it to the Sejm by 31 May for the preceding calendar year; assigned entities must report on tasks by 31 March.[36]The Strategy must be updated at least every five years, particularly in response to significant changes in oncology policy or practice.[36]

• Track strategic cancer outcomes through early-stage detection, mortality reduction and improved five-year survival.[2]Use 2025 mortality targets for colorectal, breast, cervical, melanoma and lung cancers, drawing mortality data from the National Cancer Registry.[10][19]
• Monitor screening coverage and activity, including breast, cervical and colorectal screening participation, and record screening undertaken outside publicly funded services through primary healthcare teams from 2024.[43][44][45]Target breast-screening participation of 60% by end-2024 and 75% by end-2027; colorectal screening participation of 30% and 45%; and cervical screening participation of 60% and 80%, respectively.[11]
• Assess screening quality through central coordination, intensified mammography and cervical-cytology inspections, stricter programme criteria, and mandatory certification for colposcopists and cytodiagnosticians from 2025.[12][46]
• Measure workforce progress through active nursing and midwifery numbers, training capacity, specialist numbers and occupancy of accredited training places.[14][47]Fill 100% of oncology specialisation places by end-2024 and increase doctors with oncology or related specialisations by 10% by end-2028.[15]
• Track research performance through clinical-trial participation, non-commercial trials, early-phase trial capacity, certified support centres and availability of reimbursed oncology therapies.[17]Targets include clinical-trial participation of at least 6% by 2024 and 8% by 2029, and availability of at least 90% of oncology therapies reimbursed in the European Union by 2030.[17]
• Strengthen information systems by maintaining the National Cancer Registry, organ-specific and screening registries, colorectal-screening and lung-cancer care databases, and a central clinical-trial repository.[16][42][48]Launch the National Oncology Portal by end-2022 to provide provider-level information on availability, location, effectiveness and quality of cancer care.[42]
• Verify compliance with diagnostic and therapeutic standards, including pathology and genetic diagnostics, through trained personnel, information-technology tools and mandatory accreditation arrangements.[26]Monitor patient needs and satisfaction in inpatient and outpatient oncology facilities, including social support after treatment.[18]

A complete cross-strategy indicator framework, common reporting methodology, independent evaluation arrangements and sanctions for non-performance are not specified in the supplied text.[13][17][36]

Costing & Financing

The Strategy is financed primarily from public funds, with non-public funding permitted where provided in implementation schedules.[22]Planned state-budget expenditure is capped at 250 million Polish zloty in 2020, 450 million Polish zloty annually from 2021 to 2023, and 500 million Polish zloty annually from 2024 to 2030.[41]These allocations combine current and capital funding and represent an increase to 450 million Polish zloty annually from 2021 and 500 million Polish zloty annually from 2024.[22]

• Mobilise resources from the state budget, European Union funds and Community programmes, and transfer funding previously assigned to the National Programme for Combating Cancer Diseases to corresponding Strategy activities.[22]
• Allocate annual funding between areas and activities after adoption of the annual Budget Act, with the Minister of Health determining implementation methods and scope.[37]Consider regional health-needs maps to reduce inequalities in access between voivodeships.[49]
• Permit additional funding, subject to consent from the Minister of Finance, where savings are available within the health minister’s budget; direct such resources towards critical, underfunded or new strategic areas.[41]
• Link financing to the health-expenditure commitment under the so-called 6% law, which provides for health-financing expenditure of at least 6% of gross domestic product in 2024.[41]
• Fund activities through dedicated institutional budgets where specified, including the National Health Fund for breast and cervical screening, the Medical Research Agency for clinical-research measures, and the Ministry of Science and Higher Education for biobanking legislation.[43][16][50][51]
• Use European Union funding for prevention pilots, early lung-cancer detection, workforce development and selected specialist-training support.[52][53]
• Support public financing for colorectal screening and care for families at high inherited cancer risk from 2022, following Strategy financing until end-2021.[45]Publicly finance endoprostheses for children with bone cancer through the National Health Fund from 2022.[42]
• Recognise resource pressures from fragmented provision, duplicated services, incompatible information systems, hospital equipment shortages, outdated radiotherapy accelerators and underfunded tobacco-dependence treatment clinics.[23][54][20]

Detailed annual expenditure ceilings, unit costs, financing gaps, financing splits and wider economic assumptions are not specified in the supplied text.[22][41]